**Published Ahead of Print on March 23, 2015 as 10.1200/JCO.2014.55.9898 The latest version is at** [**http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.55.9898**](http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.55.9898)

**于2015年3月23日以10.1200/JCO.2014.55.9898的形式提前出版。最新版本见**[**http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.55.9898**](http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.55.9898)

O R I G I N A L R E P O R T

JOURNAL OF CLINICAL ONCOLOGY

O R I G I N A L R E P O R T

JOURNAL OF CLINICAL ONCOLOGY

Devansu Tewari, Kaiser Permanente Irvine Medical Center, Irvine; John K. Chan, Cali- fornia Pacific/Palo Alto Medical Foundation/ Sutter Research Institute, San Francisco, CA; James J. Java, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Ritu Salani, Wexner Medical Center, Ohio State University, Columbus; Thomas Herzog, University of Cincinnati, Cincinnati, OH; Deborah K. Armstrong, Sidney Kimmel Comprehensive Cancer Center, John Hopkins University School of Medicine, Baltimore, MD; Maurie Markman, Eastern Regional Medical Center, Cancer Treat- ment Centers of America, Philadelphia, PA; Bradley J. Monk, Creighton University School of Medicine, Phoenix, AZ.

欧文凯泽永久欧文医疗中心德万苏·特瓦里；加州旧金山加州大学加州分校太平洋/帕洛阿尔托医学基金会/萨特研究所的陈约翰；纽约州布法罗市罗斯威尔公园癌症研究所妇科肿瘤组统计和数据中心的詹姆斯·j·爪哇；哥伦布俄亥俄州立大学韦克斯纳医学中心里图·萨拉尼；俄亥俄州辛辛那提市辛辛那提大学托马斯·赫尔佐格；约翰·霍普斯金大学医学院西德尼·金梅尔综合癌症中心，医学博士；美国癌症治疗中心东部区域医疗中心的莫里·马克曼，宾夕法尼亚州费城；布拉德利·蒙克，克雷顿大学医学院，亚利桑那州凤凰城。

Published online ahead of print at [www.jco.org](http://www.jco.org/) on March 23, 2015.

在印刷前在线发布于[www.jco.org](http://www.jco.org/)

Supported by National Cancer Institute Grants No. CA 27469 to the Gynecologic Oncology Group Administrative Office and No. CA 37517 to the Gynecologic Oncol- ogy Group Statistical and Data Center and by a Gynecologic Oncology Group Young Investigator Award (D.T.) and John A. Kerner Denise & Prentis Cobb Hale Research Award (J.K.C.).

由国家癌症研究所向妇科肿瘤学小组行政办公室提供的第CA 27469号拨款和向妇科肿瘤学小组统计和数据中心提供的第CA 37517号拨款以及妇科肿瘤学小组青年研究员奖(D.T .)和约翰·a·克纳·丹尼斯&普伦蒂斯·科布·黑尔研究奖(J.K.C .)支持。

Terms in blue are defined in the glos- sary, found at the end of this article and online at [www.jco.org](http://www.jco.org/).

蓝色术语在glos- sary中定义，可在本文末尾和在线上找到[www.jco.org](http://www.jco.org/)

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

作者对潜在利益冲突和作者贡献的披露见本文末尾。

Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

晚期卵巢癌腹腔化疗的长期生存优势和预后因素:一项妇科肿瘤组研究

*Devansu Tewari, James J. Java, Ritu Salani, Deborah K. Armstrong, Maurie Markman, Thomas Herzog, Bradley J. Monk, and John K. Chan*

*德万苏·特瓦里、詹姆斯·爪哇、里图·萨拉尼、黛博拉·阿姆斯壮、毛里·马克曼、托马斯·赫尔佐格、布拉德利·蒙克和约翰·陈*

See accompanying editorial doi: 10.1200/JCO.2014.60.2797

见随附的社论doi: 10.1200/JCO.2014.60.2797

**A B S T R A C T**

**A B S T R A C T**

**Purpose**

**目的**

To determine long-term survival and associated prognostic factors after intraperitoneal (IP)

确定腹腔注射后的长期生存率和相关预后因素

chemotherapy in patients with advanced ovarian cancer.

晚期卵巢癌患者的化疗。

**Patients and Methods**

**患者和方法**

Data from Gynecologic Oncology Group protocols 114 and 172 were retrospectively analyzed. Cox

对妇科肿瘤组方案114和172的数据进行回顾性分析。艇长

proportional hazards regression models were used for statistical analyses.

比例风险回归模型用于统计分析。

**Results**

**结果**

In 876 patients, median follow-up was 10.7 years. Median survival with IP therapy was 61.8

在876名患者中，中位随访时间为10.7年。IP治疗的中位生存期为61.8

months (95% CI, 55.5 to 69.5), compared with 51.4 months (95% CI, 46.0 to 58.2) for intravenous therapy. IP therapy was associated with a 23% decreased risk of death (adjusted hazard ratio [AHR], 0.77; 95% CI, 0.65 to 0.90; *P* = .002). IP therapy improved survival of those with gross

月(95%可信区间，55.5至69.5)，而静脉注射治疗为51.4个月(95%可信区间，46.0至58.2)。IP治疗与死亡风险降低23%相关(调整后的危险比[AHR]，0.77；95%置信区间，0.65至0.90；P = .002)。IP疗法提高了患有严重

residual (≤ 1 cm) disease (AHR, 0.75; 95% CI, 0.62 to 0.92; *P* = .006). Risk of death decreased

残留(≤ 1 cm)疾病(AHR，0.75；95%置信区间，0.62至0.92；P = .006)。死亡风险降低

by 12% for each cycle of IP chemotherapy completed (AHR, 0.88; 95% CI, 0.83 to 0.94; *P* < .001). Factors associated with poorer survival included: clear/mucinous versus serous histology (AHR,

IP化疗每个周期完成12%(AHR，0.88；95%置信区间，0.83至0.94；P < .001)。与较差生存率相关的因素包括:透明/粘液性与浆液性组织学(AHR，

2.79; 95% CI, 1.83 to 4.24; *P* < .001), gross residual versus no visible disease (AHR, 1.89; 95% CI, 1.48 to 2.43; *P* < .001), and fewer versus more cycles of IP chemotherapy (AHR, 0.88; 95% CI, 0.83 to 0.94; *P* < .001). Younger patients were more likely to complete the IP regimen, with a 5% decrease in probability of completion with each year of age (odds ratio, 0.95; 95% CI, 0.93

2.79;95%置信区间，1.83至4.24；P < .001)，总残留对无可见疾病(AHR，1.89；95%置信区间，1.48至2.43；P < .001)，并且IP化疗周期更少与更多(AHR，0.88；95%置信区间，0.83至0.94；P < .001)。年轻患者更有可能完成IP方案，完成的概率随着年龄的增长而降低5%(优势比，0.95；95%置信区间，0.93

to 0.96; *P* < .001).

至0.96；P < .001)。

**Conclusion**

**结论**

The advantage of IP over intravenous chemotherapy extends beyond 10 years. IP therapy

IP相对于静脉化疗的优势超过了10年。知识产权疗法

enhanced survival of those with gross residual disease. Survival improved with increasing number of IP cycles.

严重残留疾病患者的存活率提高。存活率随着IP周期数的增加而提高。

*J Clin Oncol 33. © 2015 by American Society of Clinical Oncology*

*33岁。美国临床肿瘤学会2015*

ing local therapies. Prior studies have reported on the pharmacologic advantage of delivering cisplatin

**INTRODUCTION**

当地疗法。先前的研究报道了递送顺铂的药理学优势

**INTRODUCTION**

Corresponding author: John K. Chan,

通讯作者:陈约翰，

MD, Gynecologic Oncology, California Pacific/Palo Alto Medical Foundation/ Sutter Research Institute, 3838 Califor- nia St #410, San Francisco, CA 94115; e-mail: [chanjohn@sutterhealth.org.](mailto:chanjohn@sutterhealth.org)

加州太平洋/帕洛阿尔托医学基金会/萨特研究院妇科肿瘤学医学博士，加利福尼亚州旧金山市加州大街3838号，邮编:94115；电子邮件:[chanjohn@sutterhealth.org.](mailto:chanjohn@sutterhealth.org)

© 2015 by American Society of Clinical Oncology

美国临床肿瘤学会2015

0732-183X/15/3399-1/$20.00 DOI: [10.1200/JCO.2014.55.9898](http://dx.doi.org/10.1200/JCO.2014.55.9898)

0732-183X/15/3399-1/$20.00 DOI:[10.1200/JCO.2014.55.9898](http://dx.doi.org/10.1200/JCO.2014.55.9898)

Epithelial ovarian carcinoma is the leading cause of gynecologic cancer mortality in the United States, with an associated 15,500 deaths in 2012.[1](#_bookmark7),[2](#_bookmark8) Most patients with advanced-stage cancer will eventually experience recurrence and die as a result of the dis- ease.[3](#_bookmark9) Therefore, more effective therapies are needed in the treatment of this aggressive cancer.

上皮性卵巢癌是美国妇科癌症死亡的主要原因，2012年有15，500人死亡。[1](#_bookmark7)[2](#_bookmark8) [3](#_bookmark9)

The peritoneum serves as the primary site of spread and failure in most cases of advanced can- cers. Even in the relapsed setting, the disease is typically confined to the peritoneal cavity. Thus, this region provides a sanctuary site for develop-

在大多数晚期癌症病例中，腹膜是扩散和衰竭的主要部位。即使在复发的情况下，该疾病也通常局限于腹膜腔。因此，这个地区为发展提供了一个避难所

intraperitoneally (IP), with a 20-fold higher concen- tration in the IP space compared with that measured in plasma after intravenous (IV) administration.[4](#_bookmark10)-[6](#_bookmark11) Likewise, IP paclitaxel can achieve a 1,000-fold greater concentration compared with IV administration.[7](#_bookmark12)-[12](#_bookmark15) In addition, IP therapy allows for continuous and pro- longed exposure of high drug concentrations with lower peak plasma levels over time.[13](#_bookmark16)

腹膜内给药，与静脉内给药后在血浆中测得的浓度相比，腹腔内给药的浓度高20倍。[4](#_bookmark10)[6](#_bookmark11)[7](#_bookmark12)[12](#_bookmark15)[13](#_bookmark16)

Three intergroup trials have demonstrated the survival benefit associated with IP over IV therapy in advanced, low-volume ovarian cancer.[14](#_bookmark17)-[16](#_bookmark19) Despite the positive clinical trial results and a subsequent

三项组间试验已经证明了晚期低体积卵巢癌与静脉注射治疗相关的生存益处。[14](#_bookmark17)[16](#_bookmark19)

© 2015 by American Society of Clinical Oncology **1**

2015年美国临床肿瘤学会1

Information downloaded from jco.ascopubs.org and provided by at UCSF LIBRARY & CKM on March 24, 2015 from Copyright © 2015 American S1o6c9ie.2ty30o.f2C4l3in.2ic5a2l Oncology. All rights reserved.

信息于2015年3月24日从jco.ascopubs.org下载，由UCSF图书馆和CKM提供，版权所有2015美国s1o6c 9ie . 2t 30o . f2c4l 3in . 2i C5 a2l肿瘤学。保留所有权利。

**Copyright 2015 by American Society of Clinical Oncology**

**美国临床肿瘤学会版权所有2015**

National Cancer Institute alert, IP treatment has not been widely accepted as the standard of care in the United States and is infrequently used in Europe.[13](#_bookmark16),[17](#_bookmark20) The hesitancy of clinicians to use IP therapy is likely attributed to higher toxicity, inconvenience, catheter complica- tions, and uncertain long-term benefits.[18](#_bookmark21) In the most recent trial, the majority of patients did not complete the proposed experimental IP regimen because of toxicity and other related complications.[14](#_bookmark17) Thus, it is unclear if a therapeutic advantage to increasing the number of IP cycles exists. Conversely, it is not known if there is a minimum num- ber of cycles of IP treatment needed to achieve the pharmacologic advantage and thus avoid unnecessary toxicity. In addition, there are no studies that have identified demographic and clinicopathologic characteristics of patients who may not tolerate or benefit from IP therapy, such as older patients with poor performance status or those with macroscopic residual disease. Most importantly, it is uncertain if the benefit of IP therapy persists over an extended period.

国家癌症研究所提醒，IP治疗在美国尚未被广泛接受为护理标准，在欧洲也很少使用。[13](#_bookmark16)[17](#_bookmark20) [18](#_bookmark21) [14](#_bookmark17)

As such, we report this exploratory analysis of two Gynecologic

因此，我们报告了两个妇科的探索性分析

Oncology Group (GOG) randomized phase III clinical trials to inves- tigate the 10-year survival outcomes of those who underwent IP versus IV chemotherapy. We also evaluated factors associated with survival after IP therapy, including the extent of residual disease and number of cycles of IP therapy.

肿瘤学小组(GOG)进行了随机三期临床试验，以研究接受静脉化疗和静脉化疗患者的10年生存率。我们还评估了与IP治疗后生存率相关的因素，包括残余疾病的程度和IP治疗的周期数。

**PATIENTS AND** **METHODS**

**PATIENTS AND** **METHODS**

Our study was a posthoc analysis using pooled data from all patients enrolled onto GOG protocols 114 and 172 ([Fig 1](#_bookmark0)).[15](#_bookmark18),[16](#_bookmark19) Eligibility criteria included stage III epithelial ovarian or peritoneal carcinoma with no residual disease > 1 cm in diameter after surgery. All patients had a GOG performance status of 0 to 2. Patients enrolled onto GOG 114 were randomly assigned to two different

我们的研究是一项事后分析，使用了GOG方案114和172中登记的所有患者的汇总数据([Fig 1](#_bookmark0)[15](#_bookmark18)[16](#_bookmark19)

treatment arms. Patients received either IV paclitaxel 135 mg/m2 followed by IV cisplatin 75 mg/m2 for six courses or the study arm of IV carboplatin for two

治疗武器。患者接受紫杉醇静脉注射135毫克/平方米，然后顺铂静脉注射75毫克/平方米，共六个疗程，或者接受卡铂静脉注射两个疗程

|  |
| --- |
| Enrolled onto (N = 1,018) trials  GOG-0114 (n = 589)  GOG-0172 (n = 429) Excluded (n = 142)  Did not meet (n = 76) inclusion criteria  Discontinued arm (n = 66)  Retrospectively eligible of GOG-0114 and randomly assigned  to IV or IP chemotherapy treatment  (n = 876)  Assigned to Assigned to  IV chemotherapy IP chemotherapy treatment treatment  (n = 436) (n = 440)  Continued to receive Crossed over to IV IP chemotherapy chemotherapy  treatment treatment  (n = 346) (n = 94) |

|  |
| --- |
| 参加(N = 1，018)次试验  GOG-0114 (n = 589)  GOG-0172 (n = 429)除外(n = 142)  不符合纳入标准(n = 76)  停产臂(n = 66)  GOG-0114回顾性合格，随机分配  转静脉或静脉注射化疗治疗  (n = 876)  分配给分配给  静脉化疗IP化疗治疗  (n = 436) (n = 440)  继续接受交叉静脉注射化疗  治疗处理  (n = 346) (n = 94) |

**Fig 1.** CONSORT diagram. GOG, Gynecologic Oncology Group; IP, intraperi- toneal; IV, intravenous.

图1。CONSORT图。GOG，妇科肿瘤集团；内部知识产权；四、静脉注射。

courses followed by IV paclitaxel 135 mg/m2 on day 1 and IP cisplatin 100 mg/m2 on day 8 for six courses. IV cisplatin was substituted for IP cisplatin for catheter-related malfunctions. In GOG 172, patients received 135 mg/m2 IV paclitaxel followed by either 75 mg/m2 IV cisplatin on day 2 (IV group) or 100 mg/m2 of IP cisplatin on day 2 and 60 mg/m2 of IP paclitaxel on day 8 (IP group) for six cycles. If IP cisplatin could not be administered secondary to toxicity or catheter-related issues, substitution with IV carboplatin was per- mitted. Patients who were treated provided signed informed consent consis- tent with all regulatory requirements.

疗程后，第1天静脉注射紫杉醇135 mg/m2，第8天静脉注射顺铂100 mg/m2，共6个疗程。静脉注射顺铂代替静脉注射顺铂治疗导管相关故障。在GOG 172，患者接受135毫克/平方米的静脉注射紫杉醇，然后在第2天接受75毫克/平方米的静脉注射顺铂(静脉注射组)，或在第2天接受100毫克/平方米的静脉注射顺铂，在第8天接受60毫克/平方米的静脉注射紫杉醇(静脉注射组)，共6个周期。如果顺铂不能继发于毒性或导管相关问题，建议用静脉注射卡铂替代。接受治疗的患者提供了符合所有监管要求的签署的知情同意书。

We compared baseline patient characteristics within and between the GOG studies using Pearson’s y2 test to examine relationships between cate- gorical variables and the Wilcoxon Mann-Whitney test for continuous vari- ables.[19](#_bookmark22),[20](#_bookmark23) Potential heterogeneity in treatment effect by prognostic factor subgroups was evaluated using likelihood ratio tests of subgroup-by- treatment interaction in models fitted to both the subgroups themselves and to the entire population. Kaplan-Meier estimates of survival functions included all-cause mortality and were compared using a two-sided log-rank test.[21](#_bookmark24) Hazard ratios (HRs) and CIs were estimated with Cox proportional hazards regression models to assess the relationship of treatment modality and survival outcomes adjusted for baseline demographic and clinicopathologic fac- tors.[22](#_bookmark25),[23](#_bookmark26) Overall significance of factors included in the Cox models was eval- uated with Wald tests.[24](#_bookmark27) The number of total deaths resulting from nondisease causes was low for the patient sample (44 [5%] of 876). As a preliminary step in deciding whether competing-risk analyses were warranted, we censored non- disease deaths in the multivariable Cox models. Because results of the disease- specific models were not appreciably different from those of the all-cause models, competing-risk analyses were not performed. In addition, because this analysis was exploratory and hypothesis generating, no adjustments for mul- tiple comparisons were made. All statistical analyses were performed with R software (version 2.14.2; [http://www.r-project.org](http://www.r-project.org/)).

我们使用皮尔逊y2检验比较了GOG研究内部和之间的基线患者特征，以检验类别变量和连续变量的威尔科克森曼-惠特尼检验之间的关系。[19](#_bookmark22)[20](#_bookmark23)[21](#_bookmark24)[22](#_bookmark25)[23](#_bookmark26) [24](#_bookmark27) [http://www.r-project.org](http://www.r-project.org/)

**RESULTS**

**RESULTS**

Characteristics of 876 patients included in the study are listed in [Table](#_bookmark1)

研究中包括的876名患者的特征列于[Table](#_bookmark1)

[1](#_bookmark1). Demographic and clinicopathologic characteristics of patients in the two protocols were similar (Appendix [Table A1](#_bookmark42), online only). Overall median follow-up was 10.7 years (GOG 114: median, 13.8 years; GOG 172: median, 9.7 years). In the overall study group, me- dian progression-free survival (PFS) was 25 and 20 months for the IP

[1](#_bookmark1)。两个方案中患者的人口统计学和临床病理特征相似(附录[Table A1](#_bookmark42)

and IV arms (*P* = .019), with corresponding overall survival (OS) of

和第四臂(P = .019)，相应的总生存率为

61.8 versus 51.4 months, respectively (*P* = .042; [Table 2](#_bookmark3); [Fig 2](#_bookmark2)). More

分别为61.8个月和51.4个月(P = .042[Table 2](#_bookmark3)[Fig 2](#_bookmark2)

specifically, IP therapy was associated with a 21% decreased risk of progression (adjusted HR [AHR], 0.79; 95% CI, 0.67 to 0.92; *P* = .003) and 23% decreased risk of death, with an AHR of 0.77 (95% CI, 0.65 to 0.90; *P* = .002) after adjusting for age, performance status, cell type, tumor grade, and residual disease ([Table 2](#_bookmark3)). Long-term survival rates

具体而言，IP治疗与进展风险降低21%相关(调整后的HR [AHR]，0.79；95%置信区间，0.67至0.92；P = .003)，死亡风险降低23%，AHR值为0.77 (95%置信区间，0.65-0.90；P = .002)在对年龄、表现状态、细胞类型、肿瘤分级和残留疾病([Table 2](#_bookmark3)

after IV versus IP therapy based on protocols 114 and 172 are listed in Appendix [Table A2](#_bookmark43) and [Fig A1](#_bookmark44) (online only). We evaluated factors associated with long-term survival after IP therapy ([Table 3](#_bookmark4)). Clear- cell/mucinous versus serous histology (AHR, 2.79; 95% CI, 1.83 to

附录中列出了基于方案114和172的静脉注射与静脉注射治疗后的情况[Table A2](#_bookmark43) [Fig A1](#_bookmark44) [Table 3](#_bookmark4)

4.24; *P* < .001), gross residual (≤ 1 cm) versus no visible disease (AHR, 1.89; 95% CI, 1.48 to 2.43; *P* < .001), and fewer cycles of IP chemotherapy with crossover to IV therapy (AHR, 1.43; 95% CI, 1.02 to 2.01; *P* = .041) were prognostic factors associated with poorer long-term survival after IP therapy.

4.24;P < .001)，总残留(≤ 1厘米)对比无可见疾病(AHR，1.89；95%置信区间，1.48至2.43；P < .001)，并且IP化疗与IV治疗交叉的周期更少(AHR，1.43；95%置信区间，1.02至2.01；P = .041)是与IP治疗后长期生存率较差相关的预后因素。

We then evaluated surgical factors that may predict for more benefit associated with IP therapy. Specifically, we proposed to deter- mine whether IP therapy benefits those with gross residual disease (≤ 1 cm) in addition to those with no visible disease. Our data showed that IP therapy also improved the survival of those with gross residual

然后，我们评估了手术因素，这些因素可以预测IP治疗的更多益处。具体来说，我们建议确定除了没有明显疾病的患者外，IP治疗是否对严重残留疾病(≤ 1 cm)的患者有益。我们的数据显示，IP治疗也提高了总残留患者的存活率

|  |
| --- |
| 1.0 IV  IP  0.8  0.6  0.4  0.2  0 30 60 90 120  Time (months)  No. at risk  IV 436 303 184 110 68  IP 440 337 217 140 85 |

|  |
| --- |
| 1.0四  互联网协议(Internet Protocol)  0.8  0.6  0.4  0.2  0 30 60 90 120  时间(月)  不，有危险  四436 303 184 110 68  IP 440 337 217 140 85 |

**Fig 2.** Long-term overall survival of patients treated with intravenous (IV) versus intraperitoneal (IP) chemotherapy (*P* = .04).

Overall Survival (probability)

|  |
| --- |
| **Table 1.** Overall Patient Characteristics (N = 876) Characteristic No. % |
| Age, years  Median 48.6  Range 48.6-65.6  ≤ 55.0 391 44.6  ≥ 55.0 485 55.4 |
| Race/ethnicity  White 790 90.2  Black 41 4.7  Hispanic 28 3.2  Asian 16 1.8  Other 1 0.1 |
| BMI, kg/m2  Median 24.7  Range 21.8-29.1 |
| Performance status  Normal, asymptomatic 387 44.2  Symptomatic, ambulatory 419 47.8  Symptomatic, in bed ≤ 50% 70 8.0 |
| FIGO stage III 876 100 |
| Tumor grade  1 100 11.4  2 336 38.4  3 440 50.2 |
| Histology  Serous 635 72.5  Endometrioid 83 9.5  Clear cell 35 4.0  Mucinous 16 1.8  Other 107 12.2 |
| Gross residual disease (≤ 1 cm)  No 316 36.1  Yes 560 63.9 |
| Treatment  Intravenous 436 49.8  Intraperitoneal 440 50.2 |
| GOG protocol  114 462 52.7  172 414 47.3  Abbreviations: BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; GOG, Gynecologic Oncology Group. |

图2。静脉(静脉)化疗与腹腔(静脉)化疗患者的长期总生存期(P = .04)。

Overall Survival (probability)

|  |
| --- |
| **Table 1.** Overall Patient Characteristics (N = 876) Characteristic No. % |
| Age, years  Median 48.6  Range 48.6-65.6  ≤ 55.0 391 44.6  ≥ 55.0 485 55.4 |
| Race/ethnicity  White 790 90.2  Black 41 4.7  Hispanic 28 3.2  Asian 16 1.8  Other 1 0.1 |
| BMI, kg/m2  Median 24.7  Range 21.8-29.1 |
| Performance status  Normal, asymptomatic 387 44.2  Symptomatic, ambulatory 419 47.8  Symptomatic, in bed ≤ 50% 70 8.0 |
| FIGO stage III 876 100 |
| Tumor grade  1 100 11.4  2 336 38.4  3 440 50.2 |
| Histology  Serous 635 72.5  Endometrioid 83 9.5  Clear cell 35 4.0  Mucinous 16 1.8  Other 107 12.2 |
| Gross residual disease (≤ 1 cm)  No 316 36.1  Yes 560 63.9 |
| Treatment  Intravenous 436 49.8  Intraperitoneal 440 50.2 |
| GOG protocol  114 462 52.7  172 414 47.3  Abbreviations: BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; GOG, Gynecologic Oncology Group. |

disease (AHR, 0.75; 95% CI, 0.62 to 0.92; *P* = .006; [Fig 3](#_bookmark6)). Neverthe- less, it is important to note that those with gross residual disease had a 1.89-fold increase in risk of death (95% CI, 1.48 to 2.43; *P* < .001) compared with patients with no visible disease.

疾病(AHR，0.75；95%置信区间，0.62至0.92；P = .006[Fig 3](#_bookmark6)

The overall study group of both trials showed 50% of patients in the IP arm completed six cycles of IP therapy required by the proto- cols. Because only a fraction of patients was able to complete the planned treatment, we considered the effect of treatment completion on survival. To account for the changing risk associated with chemo- therapy over time, the number of cycles of chemotherapy completed was entered into the Cox proportional hazards model as a time- varying covariate. In our analysis, risk of death decreased by 12% for each cycle of IP chemotherapy completed by any patient (AHR, 0.88; 95% CI, 0.83 to 0.94; *P* < .001). The survival rates of subgroups of patients in GOG 0172 who completed all six cycles of chemotherapy are shown in [Figure 4](#_bookmark5). Of these patients, completion of six cycles of IP chemotherapy was associated with better survival compared with three cycles of IP followed by three cycles of IV treatment (*P* = .032). Because those who completed more cycles of IP therapy had a lower risk of death, we also evaluated the demographic and clinico- pathologic factors associated with completing all six cycles of IP che- motherapy and found that younger age was associated with a higher likelihood of completing IP therapy. More specifically, the odds of completing IP therapy decreased approximately 5% for each increas- ing year of age at enrollment (odds ratio, 0.95; 95% CI, 0.93 to 0.96; *P* < .001). Other demographic and clinicopathologic factors, includ- ing performance status, were not prognostic of completing IP therapy.

两项试验的总体研究组显示，IP组中50%的患者完成了原型组所需的六个周期的IP治疗。因为只有一小部分患者能够完成计划的治疗，我们考虑了治疗完成对生存率的影响。为了说明随着时间的推移化疗相关风险的变化，已完成化疗的周期数作为时变协变量被输入Cox比例风险模型。在我们的分析中，任何患者完成的IP化疗每个周期的死亡风险降低了12%(AHR，0.88；95%置信区间，0.83至0.94；P < .001)。GOG 0172患者亚组中完成所有六个化疗周期的生存率如所示[Figure 4](#_bookmark5)

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Therapy Type | Median (months) | **Table 2.** Long-Term PFS and OS of Patients After IV Versus IP Therapy (N = 876) PFS  Range Median Range  (months) AHR 95% CI *P* (months) (months) | | | | | | OS AHR | 95% CI | *P* |
| IV | 20 | 17.7-23.5 | Referent |  | — | 51.4 | 46.0-58.2 | Referent |  | — |
| IP | 25 | 23.0-29.0 | 0.79 | 0.67 to 0.92 | .003\* | 61.8 | 55.5-69.5 | 0.76 | 0.65 to 0.90 | .002\* |
| All | 23 | 21.8-24.5 | — |  | .019† | 56.3 | 52.4-60.7 | — |  | .042† |
| Abbreviations: AHR, adjusted hazard ratio; IP, intraperitoneal; IV, intravenous; OS, overall survival; PFS, progression-free survival.  \*Log-rank test.  †Wald test. | | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 治疗类型 | 中位数(月) | 表2。静脉注射与静脉注射治疗后患者的长期全氟辛烷磺酸和OS(N = 876)  范围中位数范围  (月)AHR 95%置信区间P(月)(月) | | | | | | AHR操作系统 | 95%置信区间 | *P* |
| 注入静脉的 | 20 | 17.7-23.5 | 指示物 |  | — | 51.4 | 46.0-58.2 | 指示物 |  | — |
| 互联网协议(Internet Protocol) | 25 | 23.0-29.0 | 0.79 | 0.67至0.92 | .003\* | 61.8 | 55.5-69.5 | 0.76 | 0.65至0.90 | .002\* |
| 全部 | 23 | 21.8-24.5 | — |  | .019† | 56.3 | 52.4-60.7 | — |  | .042† |
| 缩写:AHR，调整后的危险比率；腹腔注射；四、静脉注射；OS，整体生存；PFS，无进展生存期。  \*对数秩检验。  沃尔德测试。 | | | | | | | | | | |

|  |
| --- |
| 1.0 GOG-0172 IP, 6  GOG-0172 IP, 3-5 to IV GOG-0172 IP, < 3 to IV  0.8 GOG-0172 IV, 6  0.6  0.4  0.2  0 30 60 90 120  Time (months)  No. at risk  GOG-0172 IP, 6 78 73 50 31 19  GOG-0172 IP, 3-5 to IV 26 19 14 8 4  GOG-0172 IP, < 3 to IV 61 46 30 18 7  GOG-0172 IV, 6 182 133 79 47 25 |

|  |
| --- |
| 1.0 GOG-0172 IP，6  GOG-0172 IP，3-5至IV GOG-0172 IP，< 3至IV  0.8 GOG-0172四、6  0.6  0.4  0.2  0 30 60 90 120  时间(月)  不，有危险  GOG-0172 IP，6 78 73 50 31 19  GOG-0172 IP，3-5至IV 26 19 14 8 4  GOG-0172 IP，< 3至IV 61 46 30 18 7  GOG-0172四、6 182 133 79 47 25 |

**Fig 4.** Long-term overall survival based on number of cycles of intraperitoneal (IP) therapy (*P* = .03). Analysis restricted to patients in Gynecologic Oncology Group (GOG) -0172 who completed all six cycles of chemotherapy (both IP and intravenous [IV] arms).

Overall Survival (probability)

|  |  |  |  |
| --- | --- | --- | --- |
| **Table 3.** Factors Associated With Long-Term Survival After IP Therapy Factor AHR 95% CI *P* | | | |
| Age, years | 1.01 | 1.00 to 1.02 | .137 |
| GOG performance status   1. (normal, asymptomatic) 2. (symptomatic, ambulatory) 3. (symptomatic, in bed ≤ 50%) | 1.00  0.96  1.20 | Referent  0.76 to 1.22  0.80 to 1.81 | —  .761  .371 |
| Histology  Serous, other  Clear cell or mucinous | 1.00  2.79 | Referent  1.83 to 4.24 | —  < .001 |
| Tumor grade |  |  |  |
| 1 | 1.00 | Referent | — |
| 2 | 1.68 | 1.10 to 2.58 | .017 |
| 3 | 1.49 | 0.99 to 2.25 | .056 |
| Gross residual disease\*  No Yes | 1.00  1.89 | Referent  1.48 to 2.43 | —  < .001 |
| Cycles of IP chemotherapy (zero to six) | 0.88 | 0.83 to 0.94 | < .001 |
| IV crossover†  No Yes | 1.00  1.43 | Referent  1.02 to 2.01 | —  .041 |
| Abbreviations: AHR, adjusted hazard ratio; GOG, Gynecologic Oncology Group; IP, intraperitoneal; IV, intravenous.  \*Defined as ≤ 1 cm.  †IV crossover defined as those who stopped IP chemotherapy and crossed over to IV chemotherapy. | | | |

图4。基于腹膜内治疗周期数的长期总生存率(P = .03)。分析仅限于妇科肿瘤组(GOG) -0172名完成所有六个周期化疗(静脉注射和静脉注射)的患者。

Overall Survival (probability)

|  |  |  |  |
| --- | --- | --- | --- |
| **Table 3.** Factors Associated With Long-Term Survival After IP Therapy Factor AHR 95% CI *P* | | | |
| Age, years | 1.01 | 1.00 to 1.02 | .137 |
| GOG performance status   1. (normal, asymptomatic) 2. (symptomatic, ambulatory) 3. (symptomatic, in bed ≤ 50%) | 1.00  0.96  1.20 | Referent  0.76 to 1.22  0.80 to 1.81 | —  .761  .371 |
| Histology  Serous, other  Clear cell or mucinous | 1.00  2.79 | Referent  1.83 to 4.24 | —  < .001 |
| Tumor grade |  |  |  |
| 1 | 1.00 | Referent | — |
| 2 | 1.68 | 1.10 to 2.58 | .017 |
| 3 | 1.49 | 0.99 to 2.25 | .056 |
| Gross residual disease\*  No Yes | 1.00  1.89 | Referent  1.48 to 2.43 | —  < .001 |
| Cycles of IP chemotherapy (zero to six) | 0.88 | 0.83 to 0.94 | < .001 |
| IV crossover†  No Yes | 1.00  1.43 | Referent  1.02 to 2.01 | —  .041 |
| Abbreviations: AHR, adjusted hazard ratio; GOG, Gynecologic Oncology Group; IP, intraperitoneal; IV, intravenous.  \*Defined as ≤ 1 cm.  †IV crossover defined as those who stopped IP chemotherapy and crossed over to IV chemotherapy. | | | |

**DISCUSSION**

**DISCUSSION**

Despite trials showing survival benefit, IP therapy has not been widely adopted. GOG protocol 104 did show an IP survival advantage; how- ever, cyclophosphamide was used rather than paclitaxel.[15](#_bookmark18) In GOG 114, investigators used paclitaxel, but OS was not statistically signifi- cant, and the IP arm included intensive IV carboplatin, which may have confounded the results.[16](#_bookmark19) The GOG 172 trial demonstrated that

Overall Survival (probability)

尽管试验显示了生存益处，但是IP疗法还没有被广泛采用。GOG协议104确实显示了IP生存优势；然而，使用的是环磷酰胺而不是紫杉醇。[15](#_bookmark18) [16](#_bookmark19)

Overall Survival (probability)

|  |
| --- |
| 1.0 IV + micro DS  IP + micro DS IV + gross DS  0.8 IP + gross DS  0.6  0.4  0.2  0 30 60 90 120  Time (months)  No. at risk  IV + micro DS 75 59 45 27 14  IP + micro DS 78 66 52 34 20  IV + gross DS 135 86 40 24 12  IP + gross DS 126 91 53 31 13 |

|  |
| --- |
| 1.0 IV +微DS  IP +微DS IV +毛DS  0.8 IP +总DS  0.6  0.4  0.2  0 30 60 90 120  时间(月)  不，有危险  四+微型DS 75 59 45 27 14  IP +微型DS 78 66 52 34 20  四+毛额DS 135 86 40 24 12  IP +毛DS 126 91 53 31 13 |

**Fig 3.** Long-term overall survival of patients treated with intravenous (IV) versus intraperitoneal (IP) chemotherapy based on extent of residual disease (DS; *P* < .001). NOTE. Gross residual defined as ≤ 1 cm; micro residual defined as no visible disease.

图3。根据残留疾病的程度，静脉(静脉)化疗与腹腔(腹腔)化疗患者的长期总生存率；P < .001)。注。总残留定义为≤ 1厘米；微残留定义为无可见疾病。

IV paclitaxel plus IP cisplatin and IP paclitaxel improved survival over IV paclitaxel and IV cisplatin. However, nearly half of the patients did not complete the IP regimen because of reported toxicity or associated complications. Furthermore, inferential data using cross-trial com- parisons suggested that IV carboplatin may be slightly better than IV cisplatin, and the weekly schedule in the IP arm may have partially explained the survival advantage. This suggests that the magnitude of clinical benefit with IP therapy may not have been as prominent if the control arm of GOG 172 had included carboplatin and/or weekly dosing. On the contrary, two large meta-analyses combining multiple randomized trials showed the incorporation of an IP cisplatin regimen improved the survival of patients with advanced ovarian cancer.[25](#_bookmark28),[26](#_bookmark29)

与静脉注射紫杉醇和静脉注射顺铂相比，静脉注射紫杉醇加静脉注射顺铂和静脉注射紫杉醇提高了生存率。然而，由于报告的毒性或相关并发症，近一半的患者没有完成IP方案。此外，使用交叉试验比较的推断数据表明，静脉注射卡铂可能略好于静脉注射顺铂，静脉注射组的每周时间表可能部分解释了生存优势。这表明，如果GOG 172的控制组包括卡铂和/或每周给药，IP疗法的临床益处可能没有那么显著。相反，两项结合多项随机试验的大型荟萃分析显示，联合应用顺铂方案可提高晚期卵巢癌患者的生存率。[25](#_bookmark28)[26](#_bookmark29)

Additional concerns regarding IP therapy include: increased tox- icity, multiday scheduling, lack of familiarity with catheter placement, and IP drug administration. More importantly, because median du- ration of follow-up was < 4.5 years in GOG 172, it is unknown if these

关于静脉注射治疗的其他问题包括:毒性增加、多日计划、不熟悉导管放置和静脉注射给药。更重要的是，因为GOG 172的中位随访时间< 4.5年，所以这些是否

results are sustainable after extended follow-up > 10 years. Our report

延长随访> 10年，结果可持续。我们的报告

provides 10-year data demonstrating the long-term survival advan- tage of IP over IV therapy. More specifically, IP treatment was associ- ated with a 23% decreased risk of death that remained consistent after adjusting for age, performance status, cell type, tumor grade, and residual disease.

提供了10年的数据来证明静脉注射治疗比静脉注射治疗的长期生存优势。更具体地说，IP治疗与死亡风险降低23%相关，在调整年龄、表现状态、细胞类型、肿瘤分级和残留疾病后，死亡风险保持一致。

Additional advantages of IP therapy relate to a several-fold in- crease in drug concentration in the abdominopelvic cavity compared with systemic administration.[27](#_bookmark30),[28](#_bookmark31) Despite this regional advantage, penetration into larger tumor burden may be limited; early animal studies showed that the penetration of IP drugs was limited to the superficial cell layer. Thus, IP therapy may not provide any advantage over IV treatment in patients with macroscopic residual disease.[10](#_bookmark13),[11](#_bookmark14) Most clinical investigations of IP therapy have been confined to small- volume residual disease.[12](#_bookmark15),[29](#_bookmark32)-[32](#_bookmark33) However, others have shown that pro- longed drug exposure resulting from slow absorption from the peritoneum may contribute to an IP advantage. However, it is unclear if this pharmacokinetic advantage would benefit those with gross residual disease. In our analysis, we showed a survival advantage of IP

与全身给药相比，腹腔注射疗法的其他优点涉及腹腔内药物浓度的几倍增加。[27](#_bookmark30)[28](#_bookmark31)[10](#_bookmark13)[11](#_bookmark14)[12](#_bookmark15)[29](#_bookmark32)[32](#_bookmark33)

over IV therapy in patients with both gross residual (≤ 1 cm) and no visible disease. In a prior phase II trial, investigators evaluated the efficacy of IP therapy in women with large-volume residual disease and found a PFS of 25 months versus 20 months in IP- versus IV- treated patients.[33](#_bookmark34) A potential explanation for why IP therapy is effec- tive even in large-volume residual disease is that multiple regimens of both IV and IP chemotherapies are administered over time. It is possible that the first few cycles of treatment depend on the delivery of platinum via capillary flow to reduce the size of larger residual tu- mors.[16](#_bookmark19),[34](#_bookmark35) Subsequent IP treatments delivered regionally are more effective in small residual tumors.

总残留(≤ 1 cm)且无可见疾病的患者进行静脉注射治疗。在之前的一项二期试验中，研究人员评估了IP疗法在患有大体积残留疾病的女性中的疗效，发现IP与静脉注射治疗的患者的PFS分别为25个月和20个月。[33](#_bookmark34) [16](#_bookmark19)[34](#_bookmark35)

These data are reassuring, because the most recent IP trial, GOG 252 ([ClinicalTrials.gov](http://ClinicalTrials.gov/) identifier, NCT00951496), allowed for the en- rollment of patients with larger-volume residual disease. If the long- term results from our report are confirmed, more patients might be candidates for IP treatment. It is important to note that those with gross residual disease had a 1.89-fold increase in risk of death com- pared with those with no visible residual disease. Our data confirmed a prior report on GOG trials 111, 132, 152, and 162 showing that those with microscopic residual disease or no gross residual disease had superior outcomes.[35](#_bookmark36)-[38](#_bookmark37) Our results confirm reports using data from two large prospective randomized trials and highlight the importance of complete cytoreductive surgery while suggesting a clinical benefit of IP therapy among those with gross residual disease.

这些数据令人放心，因为最近的知识产权审判，GOG 252([ClinicalTrials.gov](http://ClinicalTrials.gov/) [35](#_bookmark36)[38](#_bookmark37)

Given that fewer than half of patients in the GOG 172 IP arm com-

考虑到在GOG 172 IP分支机构中不到一半的患者

pleted the proposed therapy, and yet there was an OS advantage, some may suggest that it is not necessary to complete all six cycles of IP therapy. However, there are no studies that have evaluated the number of cycles of therapy needed to obtain the IP advantage. Our data showed that those who completed more cycles of IP therapy had superior survival. Recent studies have shown that dose-dense therapy is associated with improved outcomes. The Japanese GOG study found that dose-dense therapy with paclitaxel improved OS, with a median follow-up of 6.4 years.[39](#_bookmark38) In con- trast, aprior GOG study showed that doubling the dose of IV cisplatin and cyclophosphamide did not improve survival.[40](#_bookmark39) In fact, the strategy of increasing the dose density or dose-intensity of IV platinum agents re- sulted in significant nonhematologic toxicity related to cisplatin and thrombocytopenia resulting from carboplatin. The data from our report suggest that those who complete up to six cycles of IP therapy experience the most benefit. To achieve this, collaboration with a team of gynecologic oncologists, medical oncologists, and nursing professionals experienced in IP therapy may be required. We acknowledge that these findings may be confounded by the selection of patients who had better prognostic factors, leading to a higher likelihood of completing six cycles of chemo- therapy with better outcomes. Nevertheless, these data on improved out- come associated with more cycles of IP chemotherapy remained significant after adjusting for demographic and clinical factors including age and performance status using multivariable analysis.

完成了建议的治疗，但仍有操作系统优势，有些人可能会建议没有必要完成所有六个周期的IP治疗。然而，没有研究评估获得IP优势所需的治疗周期数。我们的数据显示，完成更多周期IP治疗的患者存活率更高。最近的研究表明，剂量密集疗法与改善结果相关。日本GOG的研究发现，紫杉醇的剂量密集疗法改善了OS，中位随访时间为6.4年。[39](#_bookmark38) [40](#_bookmark39)

Because our data showed that it is important to receive six cycles

因为我们的数据显示，接受六个周期很重要

of IP therapy, we performed an analysis to identify factors associated with completing the IP regimen. These findings may allow the clini- cian to better individualize IP therapy for those who will most likely complete and benefit from IP treatment and prevent unnecessary toxicity for those who will not tolerate this intensive regimen. Our data suggest that younger patients are more likely to complete six cycles of treatment. Prior studies have also shown that although younger pa- tients are more likely to tolerate more intensive treatment, they also

在IP治疗中，我们进行了一项分析，以确定与完成IP方案相关的因素。这些发现可能允许临床医生对最有可能完成IP治疗并从中获益的患者进行更好的个体化IP治疗，并防止那些不能耐受这种强化治疗的患者出现不必要的毒性反应。我们的数据表明，年轻患者更有可能完成六个周期的治疗。先前的研究也表明，尽管年轻患者更有可能耐受更强化的治疗，但他们也

have better survival compared with older women after adjusting for extent of cytoreductive surgery and cycles of chemotherapy.[41](#_bookmark40)

调整细胞减灭术的范围和化疗周期后，与老年妇女相比有更好的存活率。[41](#_bookmark40)

The long-term results of these trials are encouraging and provide additional support on the benefit of IP therapy while demonstrating that long-term survival end points are achievable in advanced ovarian cancer. Clinical trial investigators suggest it is challenging to demon- strate long-term survival in cancers with an extended survival after progression. This may be explained by the significant treatment ad- vances in salvage therapies, where variability in survival after progres- sion dilutes the OS comparison for the initial treatment.[42](#_bookmark41) Some investigators have suggested that OS not be used as a primary end

这些试验的长期结果令人鼓舞，并为IP治疗的益处提供了额外的支持，同时表明晚期卵巢癌可以实现长期生存终点。临床试验研究人员认为，在进展后生存期延长的癌症中，维持长期生存期具有挑战性。这可能是由于挽救疗法的显著治疗进展，进展后存活率的可变性稀释了初始治疗的OS比较。[42](#_bookmark41)

point when median survival after progression is > 12 months, but

进展后中位生存期> 12个月，但是

long-term OS results reported in our analysis suggest the contrary. We performed additional analyses in an attempt to determine the reason why IP chemotherapy prolonged OS. It is possible that IP therapy may not only extend the time to initial recurrence but also enhance re- sponse to subsequent treatment on relapse, resulting in better long- term survival. In our exploratory analyses, we found both an extension in PFS with updated follow-up data and longer survival after treat- ment for recurrence in the IP compared with IV patients. However, given the exploratory nature of this subset analysis, with a lower number of patients remaining in follow-up beyond 5 to 10 years after censoring, these findings should be interpreted with caution. Further- more, it is possible that long-term survival results may have been affected by the differences in treatment of recurrent disease, which were not controlled for in these patients.

我们分析中报告的长期OS结果表明情况恰恰相反。我们进行了额外的分析，试图确定IP化疗延长OS的原因。有可能IP治疗不仅可以延长初始复发的时间，还可以增强复发后对后续治疗的反应，从而获得更好的长期生存率。在我们的探索性分析中，我们发现，与静脉注射患者相比，静脉注射患者的随访数据更新，肿瘤复发治疗后生存期延长。然而，考虑到这种子集分析的探索性，在审查后5到10年的随访中，患者数量较少，这些发现应谨慎解释。此外，长期生存结果可能受到复发疾病治疗差异的影响，这些患者的复发疾病未得到控制。

In conclusion, to our knowledge, this report provides the first

总之，据我们所知，这份报告提供了第一个

updated results of GOG IP chemotherapy trials, showing long-term survival benefit extending beyond 10 years. Future results of the fourth phase III trial in GOG 252 will yield additional information regarding the incorporation of different approaches to IP therapy, including: dose-dense paclitaxel, antivascular targeted therapy, and maintenance therapy. Converting IP therapy into clinical practice based on the results of positive clinical trials is challenging. The long-term survival benefits described in this report may encourage more clinicians to adopt IP chemotherapy in the community. In addition, IP therapy may be implemented as a quality measure at institutions with the expertise and support teams necessary to administer IP treatment. Clinicians should support patients through the IP regimen, particu- larly if there are no significant or excessive toxicities. Lastly, the ability to better select patients who are more likely to complete IP therapy with better outcomes and less toxicity warrants further investigation as we move toward individualizing therapies.

GOG IP化疗试验的最新结果，显示长期生存获益超过10年。在GOG 252的第四个三期试验的未来结果将产生关于整合不同IP治疗方法的额外信息，包括:剂量密集紫杉醇、抗血管靶向治疗和维持治疗。将IP疗法转化为基于阳性临床试验结果的临床实践具有挑战性。本报告中描述的长期生存益处可能会鼓励更多的临床医生在社区中采用IP化疗。此外，知识产权治疗可以作为一种质量措施在具有管理知识产权治疗所需的专业知识和支持团队的机构中实施。临床医生应通过IP方案支持患者，尤其是在没有明显或过度毒性的情况下。最后，随着我们向个体化治疗迈进，更好地选择更有可能完成IP治疗且结果更好、毒性更小的患者的能力值得进一步研究。

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

*Although all authors completed the disclosure declaration, the following author(s) and/or an author’s immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.*

*尽管所有作者都完成了披露声明，但以下作者和/或作者的直系亲属表示与本文所述主题相关的财务或其他利益。某些标有“U”的关系是没有得到补偿的关系；那些标有“C”的关系得到了补偿。有关披露类别的详细说明，或有关ASCO利益冲突政策的更多信息，请参考作者披露声明和投稿人信息中的潜在利益冲突披露部分。*

**Employment or Leadership Position:** None **Consultant or Advisory Role:** None **Stock Ownership:** None **Honoraria:** Thomas J. Herzog, Johnson & Johnson, Genentech, AstraZeneca **Research Funding:** None

**就业或领导职位:无顾问或顾问角色:无股份所有权:无酬金:托马斯·j·赫尔佐格、强生、基因泰克、阿斯利康研究基金:无**

**Expert Testimony:** None **Patents, Royalties, and Licenses:** None **Other Remuneration:** None

**专家证词:无专利、版税和许可证:无其他报酬:无**

**AUTHOR CONTRIBUTIONS**

**AUTHOR CONTRIBUTIONS**

**Conception and design:** Devansu Tewari, Bradley J. Monk, John K. Chan

概念和设计:德万苏·特瓦里、布拉德利·蒙克、陈约翰

**Provision of study materials or patients:** Bradley J. Monk **Collection and assembly of data:** Devansu Tewari, James J. Java, Deborah K. Armstrong, John K. Chan

**为患者提供研究材料:布拉德利·蒙克收集和汇编数据:德万苏·特瓦里、詹姆斯·爪哇、黛博拉·阿姆斯特朗、约翰·陈**

**Data analysis and interpretation:** Devansu Tewari, James J. Java, Ritu Salani, Deborah K. Armstrong, Maurie Markman, Thomas J. Herzog, John K. Chan

**数据分析和解释:德万苏·特瓦里、詹姆斯·j·爪哇、里图·萨拉尼、德博拉·k·阿姆斯特朗、毛里·马克曼、托马斯·j·赫尔佐格、约翰·k·陈**

**Manuscript writing:** All authors

**手稿写作:所有作者**

**Final approval of manuscript:** All authors

**手稿的最终批准:所有作者**

**REFERENCES**

**REFERENCES**

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
2. 《癌症统计》，2013年。美国癌症杂志第63期:2013年11月11日至30日
3. American Cancer Society: Cancer facts and fig- ures 2012. [http://www.cancer.org/acs/groups/content/](http://www.cancer.org/acs/groups/content/%40epidemiologysurveilance/documents/document/acspc-031941.pdf) [@epidemiologysurveilance/documents/document/](http://www.cancer.org/acs/groups/content/%40epidemiologysurveilance/documents/document/acspc-031941.pdf) [acspc-031941.pdf](http://www.cancer.org/acs/groups/content/%40epidemiologysurveilance/documents/document/acspc-031941.pdf)
4. 美国癌症协会:2012年癌症事实和图表。[http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf](http://www.cancer.org/acs/groups/content/%40epidemiologysurveilance/documents/document/acspc-031941.pdf)
5. Chan JK, Cheung MK, Husain A, et al: Pat- terns and progress in ovarian cancer over 14 years. Obstet Gynecol 108:521-528, 2006
6. 陈建康，张MK，胡赛安，等:14年来卵巢癌的模式和进展。妇产科108:521-528，2006年
7. Lopez JA, Krikorian JG, Reich SD, et al: Clin- ical pharmacology of intraperitoneal cisplatin. Gyne- col Oncol 20:1-9, 1985
8. 洛佩兹·贾，克里科里安·JG，赖克·SD，等:腹腔内顺铂的临床药理学。妇科肿瘤20:1-9，1985
9. Pretorius RG, Hacker NF, Berek JS, et al: Pharmacokinetics of IP cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 67:1085-1092, 1983
10. Pretorius RG，Hacker NF，Berek JS，等:IP顺铂在难治性卵巢癌中的药代动力学。癌症治疗代表67:1085-1092，1983
11. Howell SF, Pfeifle CE, Wung WE, et al: Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43: 1426-1431, 1983
12. Howell SF，Pfeifle CE，Wung WE，等:具有全身硫代硫酸盐保护作用的腹膜内顺铂。癌症研究43: 1426-1431，1983
13. Francis P, Rowinsky E, Schneider J, et al: Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic On- cology Group pilot study. J Clin Oncol 13:2961-2967, 1995
14. 每周腹腔注射紫杉醇的第一阶段可行性和药理学研究:一项妇科手术组试点研究。13:2961-2967，1995
15. Markman M, Rowinsky E, Hakes T, et al: Phase I trial of intraperitoneal taxol: A Gynecoloic Oncology Group study. J Clin Oncol 10:1485-1491, 1992
16. 马克曼，罗文斯基，哈克斯，等:腹腔注射紫杉醇的第一期试验:妇科肿瘤组研究。10:1485-1491，1992
17. Dedrick RL, Myers CE, Bungay PM, et al: Pharmacokinetic rationale for peritoneal drug admin- istration in the treatment of ovarian cancer. Cancer Treat Rep 62:1-11, 1978
18. 《卵巢癌治疗中腹膜给药的药代动力学原理》。癌症治疗报告62:1-11，1978
19. Los G, Mutsaers PH, van der Vijgh WJ, et al: Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemo- therapy. Cancer Res 49:3380-3384, 1989
20. WJ，等:腹腔化疗后顺铂在大鼠腹腔肿瘤中的直接扩散:与全身化疗的比较。癌症研究49:3380-3384，1989
21. Los G, Mutsaers PH, Lenglet WJ, et al: Plati- num distribution in intraperitoneal tumors after intra- peritoneal cisplatin treatment. Cancer Chemother Pharmaco 25:389-394,1990
22. 等:腹腔内顺铂治疗后腹膜内肿瘤中血小板的分布。癌症化学药物25:389-394，1990
23. Howell SB, Zimm S, Markman M, et al: Long- term survival of advanced refractory ovarian carci- noma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 5:1607-1612, 1987
24. Howell SB，Zimm S，Markman M，等:腹腔化疗治疗晚期难治性小体积卵巢癌患者的长期生存。克林肿瘤杂志5:1607-1612，1987
25. Tummala MK, Alagarsamy S, McGuire WP: Intraperitoneal chemotherapy: Standard of care for patients with minimal residual stage III ovarian can- cer? Expert Rev Anticancer Ther 8:1135-1147, 1987
26. 《腹膜内化疗:最小残留三期卵巢癌患者的护理标准？抗癌专家评论8:1135-1147，1987
27. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian can- cer. N Engl J Med 354:34-43, 2006
28. 阿姆斯壮，邦迪，文泽尔，等:腹腔注射顺铂和紫杉醇治疗卵巢癌。英国医学杂志354:34-43，2006
29. Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclo- phosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovar- ian cancer. N Engl J Med 335:1950-1955, 1996
30. Alberts DS，Liu PY，Hannigan EV，等:腹腔注射顺铂加静脉注射环磷酰胺与静脉注射顺铂加静脉注射环磷酰胺治疗ⅲ期卵巢癌。《北英格兰医学杂志》335期:1950-1955年，1996年
31. Markman M, Bundy BN, Alberts DS, et al: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carbo- platin followed by intravenous paclitaxel and intra- peritoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-1007, 2001
32. Markman M，Bundy BN，Alberts DS，等:小体积III期卵巢癌标准剂量静脉注射顺铂加紫杉醇与中高剂量卡铂后静脉注射紫杉醇和腹膜内顺铂的III期试验:妇科肿瘤组、西南肿瘤组和东部协作肿瘤组的组间研究。《临床肿瘤》19:1001-1007，2001
33. Trimble EL, Christian MC: Intraperitoneal che- motherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol 100:3-4, 2006
34. Trimble EL，Christian MC:晚期上皮性卵巢癌患者的腹腔化疗。妇科肿瘤100:3-4，2006年
35. Walker JL, Armstrong DK, Huang HQ, et al: Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Gy- necol Oncol 100:27-32, 2006
36. Walker，Armstrong DK，Huang HQ，等:最佳III期卵巢癌和原发性腹膜癌静脉和腹腔化疗III期试验的腹腔内导管结果:一项妇科肿瘤学组研究。Gy- necol肿瘤科100:27-32，2006
37. Pearson K: On the criterion that a given sys- tem of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. Philosophical Magazine Series 5 50:157- 175, 1900
38. 皮尔逊:在相关变量系统的情况下，一个给定的概率偏差系统是可以合理地假设它是由随机抽样产生的。哲学杂志系列5 50:157- 175，1900
39. Mann HB, Whitney DR: On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 18:50-60, 1947
40. 关于两个随机变量中的一个是否随机大于另一个的测试。安数学统计18:50-60，1947
41. Kaplan EL, Meier P: Nonparametric estima- tion from incomplete observations. J Am Stat Assoc 53:457-481, 1958
42. 不完全观测的非参数估计。美国统计协会53:457-481，1958
43. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
44. 曼特尔N:生存数据的评估及其考虑中出现的两个新的秩次统计量。癌症化疗代表50:163-170，1966
45. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
46. 考克斯报告:回归模型和生命表。j . R . Stat Soc B34:187-220，1972
47. Wald A: Tests of statistical hypotheses con- cerning several parameters when the number of observations is large. Trans Am Math Soc 54:426- 482, 1943
48. 沃尔德答:当观测值的数量很大时，关于几个参数的统计假设的检验。跨Am数学足球54:426- 482，1943
49. Jaaback K, Johnson N, Lawrie TA: Intraperito- neal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Data- base Syst Rev 11:CD005340, 2011
50. 原发性上皮性卵巢癌初始治疗的腹腔内化疗。科克伦数据库系统第11版:CD005340，2011
51. Hess LM, Benham-Hutchins M, Herzog TJ, et al: A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian can- cer. Int J Gynecol Cancer 17:561-570, 2007
52. Hess LM，Benham-Hutchins M，Herzog TJ，等:腹腔内顺铂一线治疗卵巢癌疗效的荟萃分析。国际妇科癌症杂志17:561-570，2007
53. Cannistra SA: Cancer of the ovary. N Engl J Med 351:2519-2529, 2004
54. Cannistra SA:卵巢癌。英国医学杂志351:2519-2529，2004
55. Thigpen T: First-line therapy for ovarian carci- noma: What’s next? Cancer Invest 22:21-28, 2004 (suppl 2)
56. 卵巢癌的一线治疗:下一步是什么？癌症投资22:21-28，2004(补编2)
57. Kirmani S, Lucas WE, Kim S, et al: A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian car- cinoma. J Clin Oncol 9:649-657, 1991
58. Kirmani S，Lucas WE，Kim S，等:腹腔内顺铂和依托泊苷作为最小残留卵巢癌挽救性治疗的II期试验。《临床肿瘤》9:649-657，1991
59. Barakat RR, Sabbatini P, Bhaskaran D, et al: Intraperitoneal chemotherapy for ovarian carcinoma: Results of long-term follow-up. J Clin Oncol 20:694- 698, 2002
60. 巴拉卡特RR，萨巴蒂尼P，巴斯卡兰D，等:卵巢癌腹腔化疗:长期随访结果。《临床肿瘤》20:694- 698，2002
61. Markman M, Brady MF, Spirtos NM, et al: Phase II trial of intraperitoneal paclitaxel in carci- noma of the ovary, tube, and peritoneum: A Gyne- cologic Oncology Group study. J Clin Oncol 16: 2620-2624, 1998
62. 马克曼M，布雷迪MF，斯皮托斯n M，等:腹腔注射紫杉醇治疗卵巢、输卵管和腹膜癌的二期试验:妇科肿瘤组研究。《临床肿瘤》16: 2620-2624，1998
63. Rothenberg ML, Liu PY, Braly PS, et al: Com- bined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: Results from an intergroup phase II trial. J Clin Oncol 21:1313-1319, 2003
64. 罗森堡毫升，刘PY，布拉利PS，等:腹腔内和静脉内联合化疗治疗最佳脱瘤卵巢癌女性:组间ⅱ期试验结果。《临床肿瘤》21:1313-1319，2003
65. Fujiwara K, Nagao S, Kigawa J, et al: Compara- tive phase II study of intraperitoneal (IP) vs intravenous
66. 藤原·K，高娜·S，基加瓦·J，等:腹腔注射与静脉注射的二期比较研究

(IV) carboplatin administration with IV paclitaxel in patients with bulky residual disease after primary de- bulking surgery for epithelial ovarian or primary perito- neal cancer: A Sankai Gynecology Study Group (SGSG) study. J Clin Oncol 25:294s, 2007 (suppl; abstr 5584)

(四)在卵巢上皮性癌或原发性癌周原发性去肿块手术后伴有肿块残留疾病的患者中，卡铂联合紫杉醇静脉注射:三凯妇科研究小组(SGSG)的一项研究。《临床肿瘤》25:294，2007(增刊；abstr 5584)

1. Shapiro F, Schneider J, Markman M, et al: High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperito- neal cisplatin in advanced ovarian carcinoma: A pilot trial with ten-year follow-up. Gynecol Oncol 67:39- 45, 1997
2. 高强度静脉注射环磷酰胺和顺铂、中期手术减瘤和腹腔内顺铂治疗晚期卵巢癌:一项有十年随访的试点试验。妇科肿瘤67:39- 45，1997
3. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: A phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 23:40- 47, 1996 (suppl 12)
4. McGuire WP，Hoskins WJ，Brady MF，等:环磷酰胺和顺铂对比紫杉醇和顺铂:一项针对次优III/IV期卵巢癌患者的III期随机试验(来自妇科肿瘤组)。塞明肿瘤23:40- 47，1996(补编12)
5. Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with sub- optimal stage III or IV ovarian cancer: A gynecologic oncology group study. J Clin Oncol 18:106-115, 2000
6. Muggia FM，Braly PS，Brady MF，等:次优ⅲ期或ⅳ期卵巢癌患者顺铂与紫杉醇对比顺铂和紫杉醇的ⅲ期随机研究:一项妇科肿瘤组研究。《临床肿瘤》18:106-115，2000
7. Rose PG, Nerenstone S, Brady MF, et al: Secondary surgical cytoreduction for advanced ovar- ian carcinoma. N Engl J Med 351:2489-2497, 2004
8. 晚期卵巢癌的二次手术细胞减灭术。英国医学杂志351:2489-2497，2004
9. Winter WE 3rd, Maxwell GL, Tian C, et al: Tumor residual after surgical cytoreduction in pre- diction of clinical outcome in stage IV epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 26:83-89, 2008
10. 《预测ⅳ期上皮性卵巢癌临床结局的外科细胞减灭术后肿瘤残留:妇科肿瘤组研究》。《临床肿瘤》26:83-89，2008
11. Katsumata N, Yasuda M, Takahashi F, et al: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised con- trolled trial. Lancet 374:1331-1338, 2009
12. Katsumata N，Yasuda M，Takahashi F，等:剂量密集紫杉醇每周一次联合卡铂每3周治疗晚期卵巢癌:一项3期、开放标签、随机对照试验。柳叶刀374:1331-1338，2009
13. McGuire WP, Hoskins WJ, Brady MF, et al: Assessment of dose-intensive therapy in subopti- mally debulked ovarian cancer: A Gynecologic On- cology Group study. J Clin Oncol 13:1589-1599, 1995
14. 麦奎尔·WP，霍斯金·WJ，布雷迪·MF，等:评估低剂量强化治疗在低剂量未治疗卵巢癌中的作用:一项妇科手术组研究。13:1589-1599，1995
15. Chan JK, Loizzi V, Lin YG, et al: Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: What prognostic factors are important? Obstet Gynecol 102:156-161, 2003
16. 陈建康，卢伊兹五世，林，等:年轻女性与老年女性的三期和四期浸润性上皮性卵巢癌:哪些预后因素是重要的？妇产科102:156-161，2003年
17. Broglio KR, Barry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642-1649, 2009
18. Broglio KR，Barry DA:检测来自无进展生存的总体生存益处。美国国家癌症研究所101:1642-1649，2009

~~■ ■ ■~~

~~■ ■ ■~~

|  |
| --- |
| **GLOSSARY TERMS** |
| **maintenance therapy:** therapy intended to prolong the **progression-free survival:** time from random assignment until benefit (eg, disease remission) experienced by a patient from a death or first documented relapse, categorized as either locoregional prior primary treatment (eg, chemotherapy). (primary site or regional nodes) failure or distant metastasis or death.  **overall survival:** the duration between random assignment and death. |

|  |
| --- |
| **词汇表术语** |
| 维持治疗:旨在延长无进展生存期的治疗:从随机分配到患者从死亡或首次有记录的复发中获益(如疾病缓解)的时间，分为局部原发性治疗(如化疗)。(原发部位或区域淋巴结)衰竭或远处转移或死亡。  总生存期:随机分配和死亡之间的持续时间。 |

***Acknowledgment***

***承认***

Presented in abstract form at the Society of Gynecologic Oncology Annual Meeting, Los Angeles, CA, March 9-12, 2013.

在2013年3月9日至12日于加利福尼亚州洛杉矶举行的妇科肿瘤学会年会上以摘要形式发表。

***Appendix***

***附录***

# The following Gynecologic Oncology Group member institutions participated in the primary treatment studies: University of Alabama at Birmingham, Oregon Health Sciences University, Duke University Medical Center, Abington Memorial Hospital, University of Rochester Medical Center, Walter Reed Army Medical Center, Wayne State University, University of Minnesota Medical School, University of Southern California at Los Angeles, University of Mississippi Medical Center, Colorado Gynecologic Oncology Group, University of California at Los Angeles, University of Washington, University of Pennsylvania Cancer Center, University of Miami School of Medicine, Milton S. Hershey Medical Center, Georgetown University Hospital, University of Cincinnati, University of North Carolina School of Medicine, University of Iowa Hospitals and Clinics, University of Texas Southwestern Medical Center at Dallas, Indiana University School of Medicine, Wake Forest University School of Medicine, Albany Medical College, University of California Medical Center at Irvine, Tufts-New England Medical Center, Rush-Presbyterian-St Luke’s Medical Center, University of Kentucky, Eastern Virginia Medical School, Cleveland Clinic Foundation, Johns Hopkins Oncology Center, State University of New York at Stony Brook, Eastern Pennsylvania GYN/ONC Center, Southwestern Oncology Group, Washington University School of Medicine, Memorial Sloan-Kettering Cancer Center, Columbus Cancer Council, University of Massachusetts Medical School, Fox Chase Cancer Center, Medical University of South Carolina, Women’s Cancer Center, University of Oklahoma, University of Virginia Health Sciences Center, University of Chicago, University of Arizona Health Science Center, Tacoma General Hospital, Eastern Collaborative Oncology Group, Thomas Jefferson University Hospital, Case Western Reserve University, Tampa Bay Cancer Consortium, North Shore University Hospital, Gynecologic Oncology Network, Ellis Fischel Cancer Center, and Fletcher Allen Health Care.

# 以下妇科肿瘤组成员机构参加了初级治疗研究:阿拉巴马大学伯明翰分校、俄勒冈健康科学大学、杜克大学医学中心、阿宾顿纪念医院、罗切斯特大学医学中心、沃尔特·里德陆军医学中心、韦恩州立大学、明尼苏达大学医学院、南加州大学洛杉矶分校、密西西比大学医学中心、科罗拉多妇科肿瘤组、加州大学洛杉矶分校、华盛顿大学、宾夕法尼亚大学癌症中心、 迈阿密大学医学院、米尔顿·s·好时医学中心、乔治敦大学医院、辛辛那提大学、北卡罗来纳大学医学院、爱荷华大学医院和诊所、德克萨斯大学达拉斯西南医学中心、印第安纳大学医学院、威克森林大学医学院、奥尔巴尼医学院、加州大学欧文分校医学中心、塔夫茨-新英格兰医学中心、拉什-长老会-圣卢克医学中心、肯塔基大学东弗吉尼亚医学院、克利夫兰诊所基金会、约翰·霍普金斯肿瘤中心、 纽约州州立大学东宾夕法尼亚州立大学石溪分校GYN/ONC中心、西南肿瘤学集团、华盛顿大学医学院、纪念斯隆-凯特琳癌症中心、哥伦布癌症理事会、麻省大学医学院、福克斯蔡斯癌症中心、南卡罗来纳医科大学、妇女癌症中心、俄克拉荷马大学、弗吉尼亚大学健康科学中心、芝加哥大学、亚利桑那大学健康科学中心、塔科马总医院、东部协作肿瘤学集团、托马斯·杰斐逊大学医院、凯斯西储大学、坦帕湾癌症联盟、北岸大学医院、妇科肿瘤学网络、埃利斯·菲舍尔癌症中心、

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Table A1.** Demographic and Clinicopathologic Characteristics of Patients in GOG Protocols 114 and 172 (N = 876) GOG 114 (n = 462) GOG 172 (n = 172)  Characteristic No. % No. % *P* | | | | | | | |
| Age, years  Median Range |  | 56.6  47.4-64.9 |  |  | 57.5  49.5-66.8 |  | .047\* |
| Age, years |  |  |  |  |  |  |  |
| < 55.0 | 214 | 46.3 | 177 | 42.8 | .289† |
| ≥ 55.0 | 248 | 53.7 | 237 | 57.2 |  |
| Race/ethnicity |  |  |  |  |  |  | .003† |
| White | 418 |  | 90.5 | 372 |  | 89.9 |  |
| Black | 30 |  | 6.5 | 11 |  | 2.7 |  |
| Hispanic | 10 |  | 2.2 | 18 |  | 4.3 |  |
| Asian | 4 |  | 0.9 | 12 |  | 2.9 |  |
| Other | 0 |  | 0.0 | 1 |  | 0.2 |  |
| BMI, kg/m2‡ |  |  |  |  |  |  | .445\* |
| Median | 24.5 | 25 |  |
| Range | 21.7-28.8 | 21.9-29.3 |  |
| Performance status |  |  |  |  |  |  | .027† |
| Normal, asymptomatic | 206 |  | 44.6 | 181 |  | 43.7 |  |
| Symptomatic, ambulatory | 209 |  | 45.2 | 210 |  | 50.7 |  |
| Symptomatic, in bed < 50% | 47 |  | 10.2 | 23 |  | 5.6 |  |
| Tumor grade (differentiation) |  |  |  |  |  |  | .417† |
| 1 | 57 |  | 12.3 | 43 |  | 10.4 |  |
| 2 | 182 |  | 39.4 | 154 |  | 37.2 |  |
| 3 | 223 |  | 48.3 | 217 |  | 52.4 |  |
| Histology |  |  |  |  |  |  | < .001† |
| Serous | 308 |  | 66.7 | 327 |  | 79.0 |  |
| Endometrioid | 54 |  | 11.7 | 29 |  | 7.0 |  |
| Mucinous | 13 |  | 2.8 | 3 |  | 0.7 |  |
| Clear cell | 15 |  | 3.2 | 20 |  | 4.8 |  |
| Other | 72 |  | 15.6 | 35 |  | 8.5 |  |
| Gross residual disease |  |  |  |  |  |  | .606† |
| No | 163 | 35.3 | 153 | 37.0 |  |
| Yes | 299 | 64.7 | 261 | 63.0 |  |
| Treatment |  |  |  |  |  |  | .593† |
| IV | 226 | 48.9 | 210 | 50.7 |  |
| IP | 236 | 51.1 | 204 | 49.3 |  |
| Abbreviations: BMI, body mass index; GOG, Gynecologic Oncology Group; IP, intraperitoneal; IV, intravenous.  \*Wilcoxon test;  †Pearson’s test.  ‡Because of missing values, n = 873. | | | | | | | |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 表A1。GOG方案114和172 (N = 876) GOG方案114 (n = 462) GOG方案172 (n = 172)患者的人口统计学和临床病理特征  特征号%号% P | | | | | | | |
| 年龄，年份  中位数范围 |  | 56.6  47.4-64.9 |  |  | 57.5  49.5-66.8 |  | .047\* |
| 年龄，年份 |  |  |  |  |  |  |  |
| < 55.0 | 214 | 46.3 | 177 | 42.8 | .289† |
| ≥ 55.0 | 248 | 53.7 | 237 | 57.2 |  |
| 种族/民族 |  |  |  |  |  |  | .003† |
| 怀特（姓氏） | 418 |  | 90.5 | 372 |  | 89.9 |  |
| 黑色 | 30 |  | 6.5 | 11 |  | 2.7 |  |
| 西班牙的 | 10 |  | 2.2 | 18 |  | 4.3 |  |
| 亚洲的 | 四 |  | 0.9 | 12 |  | 2.9 |  |
| 其他的 | 0 |  | 0.0 | 一 |  | 0.2 |  |
| 身体质量指数，千克/平方米 |  |  |  |  |  |  | .445\* |
| 中位数 | 24.5 | 25 |  |
| 范围 | 21.7-28.8 | 21.9-29.3 |  |
| 性能状态 |  |  |  |  |  |  | .027† |
| 正常，无症状 | 206 |  | 44.6 | 181 |  | 43.7 |  |
| 有症状的，可走动的 | 209 |  | 45.2 | 210 |  | 50.7 |  |
| 有症状，卧床< 50% | 47 |  | 10.2 | 23 |  | 5.6 |  |
| 肿瘤分级(分化) |  |  |  |  |  |  | .417† |
| 一 | 57 |  | 12.3 | 43 |  | 10.4 |  |
| 2 | 182 |  | 39.4 | 154 |  | 37.2 |  |
| 3 | 223 |  | 48.3 | 217 |  | 52.4 |  |
| 组织学 |  |  |  |  |  |  | < .001† |
| 浆液的 | 308 |  | 66.7 | 327 |  | 79.0 |  |
| 子宫内膜样的 | 54 |  | 11.7 | 29 |  | 7.0 |  |
| 黏液的 | 13 |  | 2.8 | 3 |  | 0.7 |  |
| 透明细胞 | 15 |  | 3.2 | 20 |  | 4.8 |  |
| 其他的 | 72 |  | 15.6 | 35 |  | 8.5 |  |
| 严重残留疾病 |  |  |  |  |  |  | .606† |
| 不 | 163 | 35.3 | 153 | 37.0 |  |
| 是 | 299 | 64.7 | 261 | 63.0 |  |
| 处理 |  |  |  |  |  |  | .593† |
| 注入静脉的 | 226 | 48.9 | 210 | 50.7 |  |
| 互联网协议(Internet Protocol) | 236 | 51.1 | 204 | 49.3 |  |
| 简称:身体质量指数，体重指数；GOG，妇科肿瘤集团；腹腔注射；四、静脉注射。  \*威尔科克森试验；  皮尔逊检验。  因为缺少值，n = 873。 | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table A2.** Long-Term PFS and OS After IV Versus IP Therapy for Patients in GOG Protocols 114 and 172 PFS OS  GOG Protocol No. of No. of Median Range No. of Median Range  Arm Patients Events (months) (months) *P*\* AHR 95% CI *P*† Events (months) (months) *P*\* AHR 95% CI *P*† | | | | | | | | | | | | | | | |
| 114-IV | 226 | 191 | 22.2 | 17.8-25.1 | .131 | Referent |  | — | 174 | 52.4 | 45.1-63.8 | .216 | Referent |  | — |
| 172-IV | 210 | 173 | 18.3 | 15.6-23.3 |  | 1.09 | 0.88 to 1.34 | 0.44 | 155 | 50.4 | 43.2-58.6 |  | 1.07 | 0.85 to 1.33 | 0.57 |
| 114-IP | 236 | 197 | 27.3 | 23.4-30.7 |  | 0.83 | 0.68 to 1.01 | 0.06 | 176 | 59.6 | 52.3-69.5 |  | 0.87 | 0.71 to 1.08 | 0.21 |
| 172-IP 204 160 23.8 20.7-29.0 0.87 0.70 to 1.07 0.18 141 65.6 57.1-81.4 0.83 0.66 to 1.04 0.10 | | | | | | | | | | | | | | | |
| Abbreviations: AHR, adjusted hazard ratio; GOG, Gynecologic Oncology Group; IP, intraperitoneal; IV, intravenous; OS, overall survival; PFS, progression-free | | | | | | | | | | | | | | | |
| survival. | | | | | | | | | | | | | | | |
| \*Log-rank test. | | | | | | | | | | | | | | | |
| †Wald test. | | | | | | | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 表A2。GOG方案114和172患者静脉注射与静脉注射治疗后的长期全氟辛烷磺酸和全氟辛烷磺酸  中值范围号的GOG协议号中值范围号  手臂患者事件(月)(月)P\* AHR 95%置信区间P事件(月)(月)P\* AHR 95%置信区间 | | | | | | | | | | | | | | | |
| 114-四 | 226 | 191 | 22.2 | 17.8-25.1 | .131 | 指示物 |  | — | 174 | 52.4 | 45.1-63.8 | .216 | 指示物 |  | — |
| 172-四 | 210 | 173 | 18.3 | 15.6-23.3 |  | 1.09 | 0.88至1.34 | 0.44 | 155 | 50.4 | 43.2-58.6 |  | 1.07 | 0.85至1.33 | 0.57 |
| 114-IP | 236 | 197 | 27.3 | 23.4-30.7 |  | 0.83 | 0.68至1.01 | 0.06 | 176 | 59.6 | 52.3-69.5 |  | 0.87 | 0.71至1.08 | 0.21 |
| 172-IP 204 160 23.8 20.7-29.0 0.87 0.70至1.07 0.18 141 65.6 57.1-81.4 0.83 0.66至1.04 0.10 | | | | | | | | | | | | | | | |
| 缩写:AHR，调整后的危险比率；GOG，妇科肿瘤集团；腹腔注射；四、静脉注射；OS，整体生存；PFS，无进展 | | | | | | | | | | | | | | | |
| 生存。 | | | | | | | | | | | | | | | |
| \*对数秩检验。 | | | | | | | | | | | | | | | |
| 沃尔德测试。 | | | | | | | | | | | | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| No. at risk |  | | | | |
| GOG-0114 IV | 226 | 158 | 99 | 59 | 42 |
| GOG-0172 IV | 210 | 145 | 85 | 51 | 26 |
| GOG-0114 IP | 236 | 180 | 112 | 75 | 52 |
| GOG-0172 IP | 204 | 157 | 105 | 65 | 33 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 不，有危险 |  | | | | |
| GOG-0114四 | 226 | 158 | 99 | 59 | 42 |
| GOG-0172四 | 210 | 145 | 85 | 51 | 26 |
| GOG-0114 IP | 236 | 180 | 112 | 75 | 52 |
| GOG-0172 IP | 204 | 157 | 105 | 65 | 33 |

**Fig A1.** Long-term overall survival after intravenous (IV) versus intraperitoneal (IP) therapy based on Gynecologic Oncology Group (GOG) protocols 0114 and 0172.

1.0

0.8

GOG-0114 IV GOG-0172 IV GOG-0114 IP GOG-0172 IP

0.6

0.4

0.2

0

30

60

90

120

Time (months)

Overall Survival (probability)

图A1。根据妇科肿瘤组(GOG)方案0114和0172，静脉(静脉)与腹腔(静脉)治疗后的长期总生存率。

1.0

0.8

GOG-0114 IV GOG-0172 IV GOG-0114 IP GOG-0172 IP

0.6

0.4

0.2

0

30

60

90

120

Time (months)

Overall Survival (probability)